摘要
目的 研究外周血干细胞移植加高剂量化疗治疗小细胞肺癌的临床疗效和安全性。方法 从1994年 3月至 1999年 6月 ,对 2 0例小细胞肺癌患者应用高剂量化疗和外周血干细胞移植 ,8例处于完全缓解状态 ,12例属于挽救治疗。同种异体外周血造血干细胞移植 (Allo PBSCT) 1例 ,自体外周血造血干细胞移植(Auto PBSCT) 19例。在干细胞动员后 ,采集单个核细胞数≥ 3 .0× 10 8/kg ,CD34 +细胞数≥ 2 .0× 10 6/kg。高剂量化疗采用卡铂 35 0mg/m2 × 3天 ,足叶乙甙 12 0mg/m2 × 5天 ,表阿霉素 40mg/m2 × 2天。结果 在完全缓解状态进行外周血造血干细胞移植的 8例患者中生存时间超过 1年者 1例 ,超过 2年者 4例 ,超过 3年者 3例 (其中 2例已超过 4年 )。挽救治疗组均获得较好的近期反应 ,但没有 1例患者获得长期生存 ,中位缓解期仅为3 .5月。结论 高剂量化疗结合外周血造血干细胞移植治疗处于完全缓解状态的小细胞肺癌患者是可行的、安全的 ,但毒副反应也较严重 ,值得进一步开展临床研究。
Objective To investigate the therapeutic effect and safety of PBSCT combined with high dose chemotherapy in the treatment of small cell lung cancer(SCLC). Methods From March, 1994 to June, 1999, high dose chemotherapy combined with PBSCT was carried out in 20 patients with SCLC. Eight patients were in CR status while twelve patients were for salvaging therapy. Allo PBSCT was performed in 1 patient and Auto PBSCT in 19 patients. After mobilization of stem cell, mononeuclear cell (MNC) was collected for ≥3.0×10 8/kg, CD 34 + cell≥2.0×10 6/kg. The high dose chemotherapy included carboplatin 350?mg/m 2×3 days, VP 16 120?mg/m 2×5 days, and E ADM 40?mg/m 2×2 days. Results Encouraging results were achieved in 8 patients who were in CR status. Seven of the eight patients survived after Auto PBSCT. One patients survived more than 1 year, 4 cases over 2 years, and 3 cases over 3 years. Of the 3 patients, 2 survived more than 4 years. In the group of salvaging therapy, response was good, however there was no long term survival and median remission time was only 3.5 months. Conclusion High dose chemotherapy combined with PBSCT in the treatment of SCLC with CR status is feasible and safe, although the side effects are severe too. It is worth further studying on clinical practice.
出处
《中国肺癌杂志》
CAS
2001年第3期184-187,共4页
Chinese Journal of Lung Cancer
